Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling

Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling

Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide. Effective management for early-stage OA is crucial. Denosumab (DS) has been widely used to treat osteoporosis (OP) and rheumatoid arthritis, but its potential for managing OA remains clear. We assessed the effects of DS...

Full description

Bibliographic Details
Main Authors: Lei Shangguan, Ming Ding, Yingchun Wang, Hu Xu, Binghui Liao
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Regenerative Therapy
Subjects:
Osteoarthritis
Denosumab
Osteoclast
Chondrocyte
Online Access:http://www.sciencedirect.com/science/article/pii/S2352320424000518

Similar Items

Similar Items